Malnutrition is fairly common in endstage renal disease (ESRD) patients, persistent lack of appetite being a major symptom. Ghrelin and obestatin are two hormones that are involved in appetite and energy homeostasis. The present study examined ghrelin and obestatin levels in 24 ESRD patients undergoing haemodialysis and 24 age-matched healthy controls. Serum and saliva ghrelin and obestatin levels in the ESRD patients were significantly higher compared with controls, while saliva ghrelin and obestatin levels in all study participants were significantly higher than serum levels. Saliva ghrelin correlated with serum ghrelin and saliva obestatin correlated with serum obestatin in all study participants, although there was no correlation between ghrelin and obestatin levels. In conclusion, the results suggest that the kidneys may have a role in the metabolism and/or clearance of obestatin, as they do for ghrelin. Further studies are needed to determine if elevated levels of these hormones in ESRD patients contribute to the malnutrition that is common in these patients.
Introduction
Protein-energy malnutrition is a common factor that has an unfavourable effect on disease course in end-stage renal disease (ESRD) patients. Factors responsible for malnutrition include a lack of appetite caused by the disease, inflammation and protein loss during dialysis. The relationship between malnutrition and nutritionregulating hormones is important in ESRD and it is believed that an improvement in the nutritional status of these patients would help reduce morbidity. 1 -3 Ghrelin is a peptide hormone that helps to regulate eating behaviour and body weight.
In studies of rodents and humans, exogenous ghrelin supplementation stimulates appetite and food intake. 4 -6 This 28-amino acid hormone, secreted primarily by the stomach, was first defined by Kojima et al. 7 in 1999. Though ghrelin is mainly produced by the stomach, it is also synthesized in small quantities by other tissues. 7, 8 Ghrelin and the prepro-ghrelin gene are expressed by glomerular and renal cells. 9 It has been claimed that ghrelin, which is locally produced in the kidneys, may have endocrine and/or paracrine roles within the kidney. 9 In ESRD patients, the level of ghrelin has been found to be 2.8 times higher and B Aygen, A Dogukan, FE Dursun et al.
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this was attributed to the failure of dysfunctional kidneys to destroy and dispose of it. 10 Obestatin, which is encoded for by the same gene as ghrelin, is an anorectic peptide that has the opposite effect to that of ghrelin. 11 It has been found to be synthesized by the stomach, pancreatic islets and small intestine tissues in rats. 12, 13 Although derived from the same peptide precursor as ghrelin, obestatin suppresses food intake, inhibits jejunal contractions and prevents weight gain, however, its exact physiological role remains to be clarified. 11, 14, 15 Recent studies have failed to find a correlation between weight gain, food intake and obestatin levels. 16 -18 Obestatin has been shown to have a variety of effects on gastrointestinal motility and nutrition in experimental animal studies. 19, 20 Although ghrelin levels are elevated in ESRD patients, 10, 21 it is not yet known where obestatin is metabolized and whether it increases in renal dysfunction. This study examined the serum and saliva levels of ghrelin and obestatin in patients with ESRD compared with healthy age-matched control subjects. 
Patients and methods

PATIENTS
BLOOD SAMPLING AND MEASUREMENTS
Serum and saliva levels of ghrelin and obestatin from all participants in the study were analysed by the Department of Biochemistry, Firat University. Blood and saliva samples were collected from the healthy control group at 08:00 h following an overnight fast and from the ESRD patients at 08:00 h immediately before and just after haemodialysis. To protect peptides from proteolysis, 20 µl of aprotinin (200 kallikrein inactivator units) was added per ml of blood or saliva sample. The blood was centrifuged at 3046 g and the serum was stored at -20 ºC pending biochemical analysis for glucose, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglyceride (TG) and albumin levels.
HORMONE ASSAYS
Ghrelin levels were measured using a commercial radioimmunoassay (RIA) kit (total ghrelin [Cat. No. GHRT-89HK]; acylated ghrelin [Cat. No. GHRA-88HK]; Linco Research, St Louis, MO, USA) according to the manufacturer's instructions. Obestatin was measured using an RIA designed for measuring obestatin levels in blood (Cat. No. RK-031-92; Phoenix Pharmaceutical Inc., Burlingame, CA, USA).
STATISTICAL ANALYSIS
Data obtained in the study are expressed as mean ± SD. Statistical analysis was undertaken using the SPSS ® computer statistics software package, version 11.00 (SPSS Inc. Chicago, IL, USA). One-way variance analysis (ANOVA) and the post-ANOVA tests, Tukey B and Scheffe, were B Aygen, A Dogukan, FE Dursun et al.
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employed in the comparisons between and within groups. The same group parameters were determined by the Wilcoxon's test correlation analysis method. A P-value < 0.05 was considered statistically significant.
Results
PATIENTS AND HORMONE LEVELS
The study enrolled 24 patients with ESRD on haemodialysis and 24 age-matched healthy control subjects. The mean age (± SD) was 51.1 ± 20.3 years (range 18 -76 years) in the ESRD patient group and 42.7 ± 10.3 years (range 24 -70 years) in the healthy control group (no statistically significant betweengroup difference). The mean (± SD) duration of haemodialysis treatment was 74.4 ± 49.3 months (range 20 -210 months).
Demographic and biochemical data pertinent to the ESRD patient and control groups are presented in Table 1 . Serum and saliva ghrelin levels, both acyl and total, were significantly elevated in the pre-haemodialysis group compared with the post-haemodialysis and control groups (P < 0.001 for all comparisons). Saliva acyl and total ghrelin levels were significantly higher than serum acyl and total ghrelin levels in ESRD patients before and after haemodialysis and in the control group (P < 0.001 for all comparisons). Serum and saliva obestatin levels in ESRD patients prehaemodialysis were significantly higher than those in the control group: serum obestatin versus control P = 0.002; saliva obestatin versus control P = 0.017. Saliva obestatin levels were significantly higher than serum obestatin levels in the control group and the pre-and post-haemodialysis patients (P = 0.002, P = 0.037, P < 0.001, respectively). Similarly, there was a significant correlation between serum and saliva acyl ghrelin levels, and between serum acyl ghrelin and saliva total ghrelin levels in the control group (r = 0.875, P < 0.001; r = 0.879, P < 0.001, respectively).
CORRELATIONS IN HORMONE LEVELS
The control group demonstrated a significant correlation between serum and saliva obestatin levels (r = 0.808, P < 0.001). There was, however, no correlation between serum and saliva ghrelin levels and serum and saliva obestatin levels in the control group. Neither ghrelin nor obestatin levels in the control group were correlated with BMI, haemoglobin, glucose, HDL-cholesterol, LDL-cholesterol, TG and albumin levels (data not shown).
A significant correlation was demonstrated between serum and saliva acyl ghrelin levels in the ESRD patients pre-haemodialysis (r = 0.897, P < 0.001; Fig. 1 ). Similarly, there was a significant correlation between serum acyl ghrelin and saliva total ghrelin (r = 0.924, P < 0.001). The prehaemodialysis values from the ESRD patients also showed a significant correlation between serum and saliva obestatin levels (r = 0.864, P < 0.001; Fig. 2 ). No correlation was found between serum and saliva ghrelin and obestatin levels in the ESRD patients prehaemodialysis. Likewise, there was no correlation between ghrelin and obestatin levels in the ESRD patients prehaemodialysis with BMI, haemoglobin, glucose, HDL-and LDL-cholesterol, TG and albumin levels.
There was a significant correlation between serum acyl ghrelin and both saliva acyl ghrelin and saliva total ghrelin in the ESRD patients post-haemodialysis (r = 0.916, P < 0.001; r = 0.884, P < 0.001). A significant 
Nutrition-regulating hormones in renal disease
correlation was also found between serum total ghrelin and saliva acyl ghrelin (r = 0.924, P < 0.001) and between serum total ghrelin and saliva total ghrelin (r = 0.910, P < 0.001). Post-haemodialysis values from the ESRD patients demonstrated that serum and saliva obestatin levels were significantly correlated (r = 0.874, P < 0.001). No correlation was found between serum ghrelin and serum obestatin or between saliva ghrelin and saliva obestatin levels in the ESRD patients post-haemodialysis. Likewise, there was no correlation of ghrelin and obestatin levels with BMI, haemoglobin, glucose, HDL-and LDL-cholesterol, TG and albumin levels in the ESRD patients posthaemodialysis.
Discussion
Ghrelin is a major regulator of appetite and energy balance. 4, 22 On the other hand, for obestatin, which is encoded by the same gene as ghrelin, there are various results about its effect on nutrition and gastrointestinal motility. 11, 13, 18 To the best of the authors' knowledge, there have been no reports in the literature as to whether a dysregulated balance between ghrelin and obestatin contributes to malnutrition in ESRD patients. Ghrelin and obestatin might contribute to the mechanism of anorexia in ESRD patients and this could be clinically important in terms of disease progression.
In the present study, both saliva and serum ghrelin levels of ESRD patients were higher than those of the control group. Plasma ghrelin levels of mice that were subjected to bilateral nephrectomy were found to be significantly elevated and, thus, it was demonstrated that kidneys play an important role in the destruction and/or disposal of ghrelin. 10 In experimental 900 Nutrition-regulating hormones in renal disease studies, the ghrelin gene was shown to be expressed by kidney-derived cultured cells and ghrelin receptors were demonstrated in the glomerulus and on renal cells, such as distal tubule epithelium. 9 The presence of ghrelin in the kidney was also confirmed immunohistochemically. 23 Two different forms of ghrelin are found in tissues and body fluids. Ghrelin containing an octenyl group bound to the third amino acid series at the N-terminal edge is active (acyl) ghrelin, whereas the form of ghrelin that makes up 80 -90% of the ghrelin found in the circulation is des-acyl ghrelin. 7, 24 Acyl ghrelin was reported to be the stimulator of appetite in humans. 25, 26 As for des-acyl ghrelin, there are studies purporting that it has anorexigenic and antigastroprokinetic properties 27 -29 but it has also been argued that intra-cerebroventricular administration of des-acyl ghrelin increases feeding in rats. 30 Ghrelin levels have been found to be low in studies of obese patients and to increase with weight loss. 31, 32 In a study in anorexia nervosa patients, the patient group was found to have higher plasma ghrelin levels when compared with the control group. 33, 34 In contrast, anorectic peritoneal dialysis patients were found to have lower acyl ghrelin levels than non-anorectic ones. 35 Yoshimoto et al. 10 determined a significant increase in ghrelin levels, particularly those with carboxy-terminal immunoreactivity, in 41 patients with renal failure. 10 Muscaritoli et al. 36 found that des-acyl ghrelin was significantly higher in haemodialysis patients, especially anorectic ones, relative to the control group and they claimed that it could be associated with the pathogenesis of anorexia in these patients.
In the present study, a significant elevation in both total and acyl ghrelin levels of ESRD patients in comparison with the control group was shown. Mechanisms underlying loss of appetite in ESRD patients despite elevated ghrelin levels are not totally clear. A decline in receptor numbers or receptor insensitivity might have arisen as a compensatory response to elevated ghrelin levels in ESRD patients.
Fasting ghrelin levels have been found to be positively correlated with age, and negatively correlated with BMI and fat cell size. 37, 38 Likewise, fasting ghrelin levels displayed a significant correlation with insulin and HDL cholesterol levels. 38 Studies of patients with ESRD demonstrated a correlation between ghrelin levels and plasma insulin level, serum leptin level and truncal fat mass, but not with age or estimated protein intake. 39 In another study, ghrelin levels were found to be positively correlated with growth hormone levels, but not correlated with leptin, insulin and insulin-like growth factor-1 (IGF-1). 40 In the present study, no correlation was established between ghrelin and the analysed biochemical parameters in either the control subjects or the patients with ESRD undergoing haemodialysis. The control and ESRD groups in our study were not significantly different with regard to BMI. Inclusion of an anorectic patient group into the study and analysis of parameters such as pre-albumin, insulin, growth hormone, and IGF-1 will provide more valuable information on the role of these two hormones in ESRD patients.
Previous studies found reduced plasma total and active ghrelin levels in patients undergoing haemodialysis. 10, 41 The present study found that post-haemodialysis serum ghrelin levels were also significantly lower than pre-haemodialysis ghrelin levels and this seems to support the view that ghrelin is cleared by haemodialysis.
Ghrelin expression in the salivary gland B Aygen, A Dogukan, FE Dursun et al.
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has been demonstrated by polymerase chain reaction. 42 When total ghrelin levels in healthy individuals were compared in the same study, it was reported that the saliva contained less ghrelin than serum. 42 In contrast, another study reported that saliva ghrelin levels were higher than plasma levels. 43 The present study established that saliva ghrelin levels were higher than serum levels in the control subjects and ESRD patients. In addition, saliva ghrelin levels were significantly higher in the ESRD patients pre-haemodialysis than in the control group, and there were significant differences between pre-and posthaemodialysis saliva total and acyl ghrelin levels in ESRD patients. Saliva total and acyl ghrelin levels were correlated with serum total and acyl ghrelin levels in the control and ESRD groups.
Obestatin is encoded by the same gene as ghrelin and is an anorectic peptide that has the opposite effect to that of ghrelin. 11 Ghrelin stimulates nutrition, whereas intraperitoneal administration of obestatin inhibits nutrition and weight gain, 14, 15 however, studies have not supported the claim that central and peripheral administration of obestatin have similar effects. 16 -18 When compared with women of normal weight and anorectic women, obese women were found to have lower plasma obestatin levels. 44 Due to the increase in the ghrelin-obestatin ratio in anorectic women, it has been suggested that these hormones might be involved in the regulation of body weight. 44 On the other hand, ghrelin and obestatin were elevated in anorectic patients and reduced in obese patients. 45 On the basis of these results, it was suggested that obestatin is a nutritional marker indicating fattening of the body and insulin resistance. 45 Little is known about the metabolism of obestatin and studies on it are scarce. 46 We are not aware of any study reported in the literature that has examined the way obestatin levels change in patients with ESRD. As ghrelin and obestatin are associated with appetite and energy metabolism, it is important to know how their levels change and whether there is a correlation between these two hormones in ESRD patients. In the present study, both serum and saliva obestatin levels of ESRD patients pre-haemodialysis were significantly higher than those in the control group. Serum obestatin levels after haemodialysis dropped significantly (P = 0.009), while saliva levels did not change significantly.
In conclusion, the results of the present study demonstrate that the kidneys may have a role to play in the synthesis, metabolism and clearance of obestatin and that levels in ESRD patients increase in a similar manner to ghrelin levels. Furthermore, the results support the view that the synthesis and metabolism of these two peptides, which are derived from the same precursor, may be similar. Further studies are needed to learn how elevated ghrelin and obestatin levels in ESRD patients affect the balance between these two hormones which, in turn, might influence appetite and energy balance, and how this might contribute to malnutrition in ESRD patients.
